Discrimination of Basal Cell Carcinoma from Normal Skin Tissue Using High-Resolution Magic Angle Spinning $^1$H NMR Spectroscopy

Je-Ho Mun$^{1,2}$, Heonho Lee$^3$, Dahye Yoon$^3$, Byung-Soo Kim$^4$, Moon-Bum Kim$^4$, Shukmann Kim$^3$*

$^1$ Department of Dermatology, Seoul National University College of Medicine, Seoul, Korea, $^2$ Institute of Human-Environment Interface Biology, Seoul National University, Seoul, Korea, $^3$ Department of Chemistry, Center for Proteome Biophysics and Chemistry Institute for Functional Materials, Pusan National University, Busan, Korea, $^4$ Department of Dermatology, Pusan National University School of Medicine, Busan, Korea

* suhkmann@gmail.com

Abstract

High-resolution magic angle spinning nuclear magnetic resonance (HR-MAS NMR) spectroscopy is a useful tool for investigating the metabolism of various cancers. Basal cell carcinoma (BCC) is the most common skin cancer. However, to our knowledge, data on metabolic profiling of BCC have not been reported in the literature. The objective of the present study was to investigate the metabolic profiling of cutaneous BCC using HR-MAS $^1$H NMR spectroscopy. HR-MAS $^1$H NMR spectroscopy was used to analyze the metabolite profile and metabolite intensity of histopathologically confirmed BCC tissues and normal skin tissue (NST) samples. The metabolic intensity normalized to the total spectral intensities in BCC and NST was compared, and multivariate analysis was performed with orthogonal partial least-squares discriminant analysis (OPLS-DA). P values < 0.05 were considered statistically significant. Univariate analysis revealed 9 metabolites that showed statistically significant difference between BCC and NST. In multivariate analysis, the OPLS-DA models built with the HR-MAS NMR metabolic profiles revealed a clear separation of BCC from NST. The receiver operating characteristic curve generated from the results revealed an excellent discrimination of BCC from NST with an area under the curve (AUC) value of 0.961. The present study demonstrated that the metabolite profile and metabolite intensity differ between BCC and NST, and that HR-MAS $^1$H NMR spectroscopy can be a valuable tool in the diagnosis of BCC.

Introduction

Basal cell carcinoma (BCC), first described by Jacob in 1827, is the most common malignant neoplasm in humans [1]. In Caucasian populations in North America, the incidence of BCC has increased more than 10% a year, leading to a 30% risk of developing BCC during a lifetime [2]. BCC has become an important public health problem and is a significant burden to the
national health care service [3]. This increasing incidence is likely due to increased surveillance and a combination of multiple risk factors, which include increased sun exposure, ultraviolet or ionizing radiation, genetic defects, and immunosuppression. BCC arises from non-keratinizing cells in the basal layer of the epidermis. Although BCC grows slowly and rarely metastasizes, it can invade the surrounding tissues and cause local tissue destruction, functional impairment, and cosmetic disfiguration. Therefore, early diagnosis and treatment are crucial for a favorable prognosis.

Metabolomics describes the "quantitative measurement of time-related multiparametric metabolic responses of multicellular systems to pathophysiological stimuli or genetic modifications" [4]. Whereas genomics and proteomics focus on upstream gene and protein products, metabolomics is concerned with downstream outputs of global cellular networking [5]. Biomarkers of interest include metabolites that are intermediates and final products of metabolism. Some of these biomarkers include molecules associated with energy storage and utilization, precursors to proteins and carbohydrates, regulators of gene expression, and signaling molecules [5]. Among the various techniques used in metabolomics, high-resolution magic angle spinning (HR-MAS) 1H nuclear magnetic resonance (NMR) spectroscopy is increasingly used to investigate metabolic profiles. The advantages of 1H NMR spectroscopy include non-destructive analysis of samples, high reproducibility, minimal sample preparation processes, fast examination, and analysis of the entire sample in a single measurement [6]. Multivariate statistical methods and pattern recognition programs have been developed to handle the acquired data and search for discriminating features of biological sample sets [7]. The combination of NMR with pattern recognition methods has proven highly effective in identifying unknown metabolites that correlate with changes in genotype or phenotype [7].

The use of HR-MAS 1H NMR spectroscopy as a diagnostic tool to evaluate the metabolism of various cancers has recently been investigated. The technique has been employed to assist in the diagnosis and characterization of various cancers, including breast, lung, gastric, renal, colorectal, cervical, prostate, oral, and head and neck carcinomas [8–22]. However, to our knowledge, the metabolic profile of BCC has not been examined. Therefore, in the present study, we investigated the metabolic profile of BCC using 1H HR-MAS spectroscopy.

Materials and Methods

We carried out this study with histopathologically confirmed cutaneous BCC and normal skin tissues (NSTs). All tissues were acquired from patients with skin cancers who underwent Mohs micrographic surgery at the dermatologic surgical clinic of Pusan National University Yangsan Hospital. During the first stage of Mohs micrographic surgery, the main tumor was carefully excised. After confirmation of complete tumor removal, the resultant surgical defect was repaired by reconstructive surgery. NST was acquired from dog ear repair or flap surgery when available. All tumor and NST tissues were divided into 2 sections. Part of each tissue was sent to the pathology department to confirm the histopathologic diagnosis of the samples, and the other part of the tissue was immediately snap-frozen in liquid nitrogen and stored at -80°C until NMR analysis.

This study was approved by the institutional review board of Pusan National University Yangsan Hospital, and written informed consent was obtained from every patient. The study was conducted in compliance with the principles of the Declaration of Helsinki.

Sample collection and preparation

Tissues were immediately frozen and stored at -80°C until analysis. Twenty-five milligrams of each sample was weighed prior to NMR analysis. The weighed tissue was then transferred to a
4-mm nanotube with 25 μL deuterium oxide to provide field lock, and 2 mM TSP-d4 (3-(trimethylsilyl) propionic-2,2,3,3-d4 acid sodium salt) as a reference. The rotor was capped, and the spinning speed was monitored and recorded. Samples were prepared as rapidly as possible in order to prevent contamination or enzymatic decomposition.

**NMR spectroscopy**

All spectra were acquired at 600.167 MHz using an Agilent spectrometer operating at 1H frequency and equipped with a 4-mm gHX NanoProbe. High-resolution 1H NMR metabolic profiling of the biopsied tissue samples was achieved using magic angle spinning (MAS) at 54.7° with respect to the direction of the magnetic field. All data were collected at a spinning rate of 2,000 Hz, and the spectra were checked between the water peak and side band, which coincides with the spin rate. Spectra were acquired using the presat-CPMG (Carr-Purcell-Meiboom-Gill) pulse sequence to suppress water and high molecular mass compounds. The acquisition time was 1.704 sec and relaxation delay time was 1 sec. In total, 128 scans were collected at a spectral width of 9615.4 Hz at 299.1 K. A total measurement time of 8 min 13 sec was required per sample. All data were Fourier-transformed and calibrated to TSP-d4 as 0.00 ppm using Chenomx NMR Suite 7.1 professional software (Chenomx Inc., Edmonton, Canada).

**Data analysis**

All spectra were processed and assigned using Chenomx NMR Suite 7.1 professional and the Chenomx 600 MHz library database. The Chenomx NMR Suite is an integrated set of tools that allows for the identification and quantification of metabolites in an NMR spectra. The Chenomx reference libraries contain hundreds of fully searchable pH dependent compound models. Single peaks were confirmed by analysis of each spike, and the overlapped data were analyzed by a 2D correlation spectroscopy (COSY) NMR spectrum (S1 Fig). All data were converted to the frequency domain, corrected for phase and baseline, and then the TSP-d4 singlet peak was adjusted to 0.00 ppm. The target profiling method involved the confirmation of changes in a specific metabolite, followed by the comparison of data from the normal and cancer samples using Chenomx. The pattern recognition process required statistical analysis software. In this study, the SIMCA-P+ 12.0 software package (Umetrics, Umea, Sweden) was utilized to identify differences in the metabolite profile and metabolite intensity of normal and cancer data. The spectra were normalized to the total area and then binned within 0.001 ppm using Chenomx. The water region (4.6 ppm to 4.7 ppm) and the reference peak were excluded prior to analysis. The orthogonal partial least-squares discriminant analysis (OPLS-DA) was performed with Pareto scaling to differentiate between the cancer and normal group. The quality of the model was demonstrated by the cross-validation parameters $R^2$ and $Q^2$. The relative concentrations of marker metabolites of BCC and NST were compared. Statistical analyses of the levels were performed using commercial software (PASW, Version 17; SPSS Inc., Chicago, IL, USA; MedCalc, Mariakerke, Belgium). Student’s t-test was used for the comparison of the proportions. A P value lower than 0.05 was considered statistically significant. A receiver operation characteristic (ROC) curve was generated using a web server for metabolomics data analysis (MetaboAnalyst 3.0). [23]

**Results**

**Baseline characteristics of patients and tissue samples**

HR-MAS 1H NMR spectroscopic data were analyzed for all tissue samples, which included histopathologically confirmed 15 BCC tissues and 15 NST samples. The age of BCC patients
ranged from 44 to 84 years with a mean of 67.3 ± 12.3 years. The patients consisted of four males (27%) and 11 females (73%). The histopathologic subtypes of BCC included nodular (n = 6), micronodular (n = 6), infiltrative (n = 2), and superficial (n = 1). NST samples were acquired from 10 BCC patients; additional five normal tissues were collected from patients with other cancers who underwent surgical treatment.

Differences in metabolic profiling and univariate analysis

The representative stacked HR-MAS 1H NMR spectra of BCC and NST are shown in Fig 1. Visual comparison of the spectra showed a variable degree of metabolites. In general, the level of lipid/triglyceride (TG) was higher in NST samples compared to the BCC samples. However, the exact level of lipid/TG was not compared because lipid/TG consist of several analog compounds. The mean quantities of marker metabolites used for the distinction of BCC and NST are shown in Table 1. The total areas of normalized spectra were used to calculate relative intensities of each metabolite presented as mean ± SEM. A selective non-overlapping resonance from each metabolite was used to calculate relative intensities. Among the marker metabolites examined for comparison of BCC and NST, the levels of 9 metabolites were significantly different. The levels of alanine (P = 0.005), aspartate (P = 0.011), glycine (P = 0.005), and phosphocholine (P = 0.021) were significantly elevated, and those of acetate (P = 0.008), creatine (P = 0.021), fumarate (P = 0.010), isoleucine (P < 0.001), and lactate (P = 0.016) decreased in BCC samples. Fig 2 presents the relative concentration of these metabolites in BCC and NST tissues.

Multivariate analysis

OPLS-DA score plot discriminated BCC from NST with a good description of the data ($R^2_X = 0.784, R^2_Y = 0.855$) and a good prediction accuracy for new data ($Q^2 = 0.679$) (Fig 3). Metabolites with statistically significant differences in univariate analysis were included for the generation of ROC curves. ROC curves generated from the results revealed excellent discrimination of BCC from NST, which yielded an AUC value of 0.961 (Fig 4).

Discussion

Recent advances in analytical biochemistry have led to the development of an array of metabolic profiling platforms with which to exploit the metabolome [24]. Recently, the application of HR-MAS NMR for the differentiation of the metabolic profiles of cancer and normal tissue has been explored for a variety of cancer types [25]. In the present study, we have applied HR-MAS 1H NMR spectroscopy combined with biostatistical methods to explore the metabolic profiling of BCC. To our knowledge, this is the first study to investigate the metabolite profile and metabolite intensity of BCC using HR-MAS 1H NMR.

The present study demonstrated that HR-MAS 1H NMR spectroscopy was able to discriminate BCC from normal skin tissue. The OPLS-DA models derived from the current metabolic analysis illustrates a clear separation between BCC and normal skin tissues, and thus demonstrates the potential of this statistical analytic approach in metabolomics. The univariate analysis found 9 metabolites that were significantly different between BCC and NST. The ROC curve generated from the results showed an excellent discrimination of BCC from NST (AUC value of 0.961).

The level of glycine was higher in BCC samples. Glycine is formed from the glycolytic intermediate 3-phosphoglycerate, and is an important source of one-carbon units for de novo purine synthesis [26]. Therefore, the increased levels of glycine could indicate enhanced
nucleotide synthesis in BCC. Elevated glycine levels have been previously reported in other cancers, including breast, brain, ovarian, and colorectal cancer, in an MAS NMR study [13, 27–29].

The level of alanine was also higher in BCC samples. Alanine is a major source of energy for metabolism and a principal end-product of glycolysis/glutaminolysis in tumor proliferation and growth. Increased alanine levels were reported in other cancers such as prostatic and bladder cancers [12, 17]. Aspartate is a metabolite involved in the urea cycle and participates in gluconeogenesis. Therefore, the increased level of aspartate in BCC samples may be associated with gluconeogenesis.

Choline compounds are regarded as a marker of increased membrane turnover and are expected to increase in malignant tumors [30]. MRS techniques have detected alteration in the levels of choline-containing compounds in vivo in breast cancer patients and are now used for their diagnosis and prognosis [31]. The results of this study showed that the levels of phosphocholine were elevated in BCC. Therefore, the measurement of phosphocholine in patients with BCC by HR-MAS 1H NMR spectroscopy could be used as a biomarker for the diagnosis and prognosis of BCC patients.

Levels of acetate, creatine, fumarate, and isoleucine were lower in the BCC samples. We assume that the increased energy consumption of certain metabolites by the BCC cells may be associated with the decreased levels of these metabolites. In this study, lactate levels were also lower in the BCC samples. Previous studies have shown that increased lactate levels were detected in various cancer tissues [12, 25]. High concentrations of lactate in solid tumors have been associated with a high incidence of metastasis in the early stages of the disease, whereas lower concentrations of lactate indicate a longer and disease-free survival [32]. The low level of

Fig 1. A representative 600 MHz 1H HR-MAS CPMG NMR spectra of normal skin (A) and basal cell carcinoma (C). Histopathologic images of normal skin (A) and basal cell carcinoma (D) (hematoxylin and eosin, original magnification X 100).

doi:10.1371/journal.pone.0150328.g001
lactate in BCC may be attributed to the fact that BCC is a slowly growing, low-grade malignant tumor with rare metastatic potential.

The present study has some limitations. First, the results of this study are limited by a small sample size. Considering the many factors affecting metabolite changes in the tumor such as the histopathologic grade and heterogeneity of the tumor microenvironment, further studies with a larger sample size and different histopathologic subtypes are necessary to establish the metabolite profiles of BCC. Second, instead of analyzing fresh tissues, the tissues were preserved using the snap freezing technique, which could have affected the metabolite profile. Although some metabolic alteration is unavoidable, freezing the sample immediately after

**Table 1. The relative concentrations of marker metabolites acquired by HR-MAS \(^1\)H NMR spectroscopy from basal cell carcinoma (BCC) and normal skin tissue (NST). Metabolites that were significantly different between tissues are shown in bold.**

| Metabolite       | BCC Mean | BCC SE  | NST Mean | NST SE  | P values |
|------------------|----------|---------|----------|---------|----------|
| Acetate          | 1.0268   | 0.1432  | 1.8791   | 0.2593  | **0.008**|
| Alanine          | 8.7665   | 0.4817  | 6.7766   | 0.4471  | **0.005**|
| Arginine         | 2.4139   | 0.1336  | 2.5541   | 0.1673  | 0.518    |
| Asparagine       | 1.4250   | 0.1105  | 1.2705   | 0.1259  | 0.364    |
| Aspartate        | 2.8929   | 0.2526  | 1.9180   | 0.2504  | **0.011**|
| Choline          | 2.4864   | 0.3436  | 1.8362   | 0.1363  | 0.089    |
| Creatine         | 0.9183   | 0.0938  | 1.2907   | 0.1205  | 0.021    |
| Cysteine         | 0.9530   | 0.0948  | 1.0404   | 0.0910  | 0.511    |
| Formate          | 1.0704   | 0.2917  | 1.4826   | 0.3052  | 0.337    |
| Fumarate         | 0.0814   | 0.0101  | 0.1305   | 0.0144  | **0.010**|
| Glutamate        | 7.2551   | 0.3589  | 8.0161   | 0.6114  | 0.292    |
| Glutamine        | 2.2904   | 0.1428  | 2.7292   | 0.1716  | 0.059    |
| Glutathione      | 0.2297   | 0.0305  | 0.3414   | 0.0875  | 0.238    |
| Glycine          | 10.9154  | 0.5805  | 6.6196   | 0.3819  | <0.001   |
| Inosine          | 0.1623   | 0.0184  | 0.2156   | 0.0207  | 0.064    |
| Isobutyrate      | 0.1186   | 0.0098  | 0.1391   | 0.0195  | 0.353    |
| Isoleucine       | 1.4826   | 0.1227  | 2.1733   | 0.1183  | <0.001   |
| Lactate          | 17.5850  | 1.1913  | 22.9847  | 1.7356  | **0.016**|
| Leucine          | 3.7121   | 0.2335  | 4.5711   | 0.3532  | 0.052    |
| Lysine           | 1.9224   | 0.2278  | 1.9653   | 0.1956  | 0.887    |
| Methionine       | 0.4716   | 0.0568  | 0.5554   | 0.0531  | 0.290    |
| Phosphocholine   | 0.7126   | 0.0735  | 0.4911   | 0.0523  | **0.021**|
| Phosphoethanolamine | 2.7927  | 0.2385  | 2.2828   | 0.1364  | 0.074    |
| Phenylalanine    | 1.3016   | 0.0967  | 1.1206   | 0.0870  | 0.175    |
| Serine           | 7.8613   | 0.3669  | 7.5939   | 0.4621  | 0.654    |
| Succinate        | 0.0941   | 0.0160  | 0.1771   | 0.0390  | 0.059    |
| Taurine          | 5.1967   | 0.2901  | 4.6112   | 0.3319  | 0.195    |
| Threonine        | 3.6117   | 0.2556  | 3.5584   | 0.2167  | 0.875    |
| Tyrosine         | 1.1208   | 0.1013  | 0.8584   | 0.0807  | 0.052    |
| Uracil           | 0.3693   | 0.0417  | 0.3754   | 0.0259  | 0.902    |
| Valine           | 3.3027   | 0.1868  | 3.1011   | 0.2190  | 0.490    |
| myo-Inositol     | 2.2990   | 0.2269  | 2.4508   | 0.1406  | 0.574    |
| sn-Glycero-3-phosphocholine | 1.7196 | 0.1681  | 1.5840   | 0.1129  | 0.509    |

doi:10.1371/journal.pone.0150328.t001
Fig 2. The percent change in metabolite levels in basal cell carcinoma tissues relative to the levels in normal tissues. % Change = ([basal cell carcinoma]−[normal])/[normal] × 100. The concentrations of the metabolites were calculated from the integration of peak areas using Chenomx.

doi:10.1371/journal.pone.0150328.g002

Fig 3. Multivariate analysis of 1H NMR spectra from basal cell carcinoma (BCC) and normal skin tissue (NST). (A) The OPLS-DA score plot clearly discriminates BCC from NST. (B) The corresponding loading plot.

doi:10.1371/journal.pone.0150328.g003
excision, minimizing the sample preparation time, and acquiring the MAS data at a low temperature can minimize degradation \[15\].

In conclusion, the HR-MAS $^1$H NMR-based metabolomic analysis showed a significant difference in the metabolic profiles of BCC and normal skin tissues. The results of this study suggest that HR-MAS $^1$H NMR spectroscopy can be a valuable tool in the diagnosis of BCC.

Supporting Information

S1 Fig. A representative 2D-NMR COSY spectrum of normal skin tissue. (TIF)

Author Contributions

Conceived and designed the experiments: JHM SMK. Performed the experiments: JHM HHL DHY SMK. Analyzed the data: JHM HHL DHY SMK. Contributed reagents/materials/analysis tools: JHM BSK MBK. Wrote the paper: JHM HHL. Edited the manuscript: DHY BSK MBK SMK.

References

1. Crowson AN. Basal cell carcinoma: biology, morphology and clinical implications. Modern Pathology. 2006; 19:S127–S47. doi: 10.1038/modpathol.3800512. ISI:000234897200009. PMID: 16446711

2. Wong CSM, Strange RC, Lear JT. Basal cell carcinoma. British Medical Journal. 2003; 327(7418):794–8. doi: 10.1136/bmj.327.7418.794. ISI:000185805100025. PMID: 14525881

3. Lomas A, Leonard-Bee J, Bath-Hextall F. A systematic review of worldwide incidence of nonmelanoma skin cancer. Br J Dermatol. 2012; 166(5):1069–80. Epub 2012/01/19. doi: 10.1111/j.1365-2133.2012.10830.x PMID: 22251204.
4. Nicholson JK, Lindon JC, Holmes E. 'Metabonomics': understanding the metabolic responses of living systems to pathophysiological stimuli via multivariate statistical analysis of biological NMR spectroscopic data. Xenobiotica. 1999; 29(11):1181–9. Epub 1999/12/22. doi: 10.1080/004982599238047 PMID: 10598751.

5. Davis VW, Bathe OF, Schiller DE, Slupsky CM, Sawyer MB. Metabolomics and surgical oncology: Potential role for small molecule biomarkers. J Surg Oncol. 2011; 103(5):451–9. Epub 2011/03/15. doi: 10.1002/jso.21831 PMID: 21400531.

6. Emwas A-H, Salek R, Griffin J, Merzaban J. NMR-based metabolomics in human disease diagnosis: applications, limitations, and recommendations. Metabolomics. 2013; 9(5):1048–72. doi: 10.1007/s11306-013-0524-y

7. Zhang AH, Sun H, Qiu S, Wang XJ. NMR-based metabolomics coupled with pattern recognition methods in biomarker discovery and disease diagnosis. Magn Reson Chem. 2013; 51(9):549–56. Epub 2013/07/06. doi: 10.1002/mrc.3985 PMID: 23826598.

8. Chen W, Zu Y, Huang Q, Chen F, Wang G, Lan W, et al. Study on metabolonomic characteristics of human lung cancer using high resolution magic-angle spinning 1H NMR spectroscopy and multivariate data analysis. Magn Reson Chem. 2011; 66(6):1531–40. Epub 2011/04/28. doi: 10.1002/mrm.22957 PMID: 21523825.

9. Sitter B, Bathen TF, Singstad TE, Fjosne HE, Lundgren S, Halgunset J, et al. Quantification of metabolites in breast cancer patients with different clinical prognosis using HR MAS MR spectroscopy. NMR Biomed. 2010; 23(4):24–31. Epub 2010/01/27. doi: 10.1002/nbm.1478 PMID: 20101607.

10. Rocha CM, Barros AS, Gil AM, Goodfellow BJ, Humphrey E, Spraul M, et al. Metabolic profiling of human lung cancer tissue by 1H high resolution magic angle spinning (HRMAS) NMR spectroscopy. J Proteome Res. 2010; 9(1):319–32. Epub 2009/11/17. doi: 10.1021/pr9006574 PMID: 19908917.

11. Yang Y, Li C, Nie X, Feng X, Chen W, Yue Y, et al. Metabonomic studies of human hepatocellular carcinoma using high-resolution magic-angle spinning 1H NMR spectroscopy in conjunction with multivariate data analysis. J Proteome Res. 2007; 6(7):2605–14. Epub 2007/06/15. doi: 10.1021/pr070063h PMID: 17564425.

12. Tripathi P, Somashekar BS, Ponnusamy M, Gursky A, Dailey S, Kunju P, et al. HR-MAS NMR tissue metabolome signatures cross-validated by mass spectrometry distinguish bladder cancer from benign disease. J Proteome Res. 2013; 12(7):3519–28. Epub 2013/06/05. doi: 10.1021/pr4004135 PMID: 23731241; PubMed Central PMCID: PMC3722911.

13. Chan EC, Koh PK, Mal M, Cheah PY, Eu KW, Backshall A, et al. Metabolic profiling of human colorectal cancer using high-resolution magic angle spinning nuclear magnetic resonance (HR-MAS NMR) spectroscopy and gas chromatography mass spectrometry (GC/MS). J Proteome Res. 2009; 8(1):352–61. Epub 2008/12/10. doi: 10.1021/pr8006232 [pii] PMID: 19063642.

14. Mirnezami R, Jimenez B, Li JV, Kinross JM, Veselkov K, Goldin RD, et al. Rapid diagnosis and staging of colorectal cancer via high-resolution magic-angle spinning 1H NMR spectroscopy in conjunction with multivariate data analysis. J Proteome Res. 2007; 6(7):2605–14. Epub 2007/06/15. doi: 10.1021/pr070063h PMID: 17564425.

15. De Silva SS, Payne GS, Thomas V, Carter PG, Ind TE, deSouza NM. Investigation of metabolite changes in the transition from pre-invasive to invasive cervical cancer measured using (1)H and (31)P magic angle spinning MRS of intact tissue. NMR Biomed. 2009; 22(2):191–8. Epub 2008/10/04. doi: 10.1002/nbm.1302 PMID: 18833545.

16. Cheng LL, Burns MA, Taylor JL, He W, Halperm EF, McDougall WS, et al. Metabolic characterization of human prostate cancer with tissue magnetic resonance spectroscopy. Cancer Res. 2005; 65(8):3030–4. Epub 2005/04/19. 65/8/3030 [pii] PMID: 15833828.

17. Tesserem MB, Swanson MG, Keshari KR, Albers MJ, Jouin D, Tabatabai ZL, et al. Evaluation of lactate and alanine as metabolic biomarkers of prostate cancer using 1H HR-MAS spectroscopy of biopsy tissues. Magn Reson Med. 2008; 60(3):510–6. Epub 2008/08/30. doi: 10.1002/mrm.21694 PMID: 18727052; PubMed Central PMCID: PMC2613807.

18. Wei J, Xie G, Zhou Z, Shi P, Qiu Y, Zheng X, et al. Salivary metabolite signatures of oral cancer and leukoplakia. Int J Cancer. 2011; 129(9):2207–17. Epub 2010/12/31. doi: 10.1002/ijc.25881 PMID: 21190195.

19. Somashekar BS, Kamarajan P, Danciu T, Kapila YL, Chinnaiaiyam A, Rajendiran TM, et al. Magic angle spinning NMR-based metabolic profiling of head and neck squamous cell carcinoma tissues. J Proteome Res. 2011; 10(11):5232–41. Epub 2011/10/04. doi: 10.1021/pr200800w PMID: 21961579; PubMed Central PMCID: PMC3208743.

20. Choi JS, Baek HM, Kim S, Kim MJ, Youk JH, Moon HJ, et al. HR-MAS MR Spectroscopy of Breast Cancer Tissue Obtained with Core Needle Biopsy: Correlation with Prognostic Factors. Plos One. 2012; 7(12). ARTN e51712 doi: 10.1371/journal.pone.0051712. ISI:000312386800070. PMID: 23272149
21. Choi JS, Baek HM, Kim S, Kim MJ, Youk JH, Moon HJ, et al. Magnetic Resonance Metabolic Profiling of Breast Cancer Tissue Obtained with Core Needle Biopsy for Predicting Pathologic Response to Neoadjuvant Chemotherapy. Plos One. 2013; 8(12). UNSP e83866 doi: 10.1371/journal.pone.0083866. ISI: 000328741900024. PMID: 24367616

22. Giskeodegard GF, Bertilsson H, Selnaes KM, Wright AJ, Bathen TF, Viset T, et al. Spermine and Citrate as Metabolic Biomarkers for Assessing Prostate Cancer Aggressiveness. Plos One. 2013; 8(4). ARTN e62375 doi: 10.1371/journal.pone.0062375. ISI: 000318008400175. PMID: 23626811

23. Xia JG, Sinelnikov IV, Han B, Wishart DS. MetaboAnalyst 3.0-making metabolomics more meaningful. Nucleic Acids Research. 2015; 43(W1):W251–W7. doi: 10.1093/nar/gkv380. ISI: 000359772700039. PMID: 25897128

24. Mirmezami R, Kinross JM, Vorkas PA, Goldin R, Holmes E, Nicholson J, et al. Implementation of molecular phenotyping approaches in the personalized surgical patient journey. Ann Surg. 2012; 255(5):881–9. Epub 2011/12/14. PMID: 22156927.

25. Moestue S, Sitter B, Bathen TF, Tessem MB, Gribbestad IS. HR MAS MR spectroscopy in metabolic characterization of cancer. Curr Top Med Chem. 2011; 11(1):2–26. Epub 2010/09/03. BSP/CTMC/E-Pub/-0007-11-1 [pii]. PMID: 20809888.

26. Fu TF, Rife JP, Schirch V. The role of serine hydroxymethyltransferase isozymes in one-carbon metabolism in MCF-7 cells as determined by (13)C NMR. Arch Biochem Biophys. 2001; 393(1):42–50. Epub 2001/08/23. doi: 10.1006/abbi.2001.2471 S0003-9861(01)92471-3 [pii]. PMID: 11516159.

27. Sitter B, Lundgren S, Bathen TF, Halgunset J, Fjosne HE, Gribbestad IS. Comparison of HR MAS MR spectroscopic profiles of breast cancer tissue with clinical parameters. NMR Biomed. 2006; 19(1):30–40. Epub 2005/10/18. doi: 10.1002/nbm.992 PMID: 16229059.

28. Righi V, Andronesi OC, Mintzopoulos D, Black PM, Tzika AA. High-resolution magic angle spinning magnetic resonance spectroscopy detects glycine as a biomarker in brain tumors. Int J Oncol. 2010; 36 (2):301–6. Epub 2010/01/01. PMID: 20043062; PubMed Central PMCID: PMC3715372.

29. Denkert C, Budczies J, Kind T, Weichert W, Tablack P, Sehouli J, et al. Mass spectrometry-based metabolic profiling reveals different metabolite patterns in invasive ovarian carcinomas and ovarian borderline tumors. Cancer Res. 2006; 66(22):7079–804. Epub 2006/11/17. 66/22/10795 [pii] doi: 10.1158/0008-5472.CAN-06-0755 PMID: 17108116.

30. Griffin JL, Shockcor JP. Metabolic profiles of cancer cells. Nat Rev Cancer. 2004; 4(7):551–61. Epub 2004/07/02. doi: 10.1038/nrc1390 nrc1390 [pii]. PMID: 15229480.

31. Bolan PJ, Meisamy S, Baker EH, Lin J, Emory T, Nelson M, et al. In vivo quantification of choline compounds in the breast with 1H MR spectroscopy. Magn Reson Med. 2003; 50(6):1134–43. Epub 2003/12/04. doi: 10.1002/mrm.10654 PMID: 14648561.

32. Walenta S, Schroeder T, Mueller-Klieser W. Lactate in solid malignant tumors: Potential basis of a metabolic classification in clinical oncology. Current Medicinal Chemistry. 2004; 11(16):2195–204. ISI:000222533300008. PMID: 15279558